A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of Cp-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer.

Trial Profile

A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of Cp-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2014

At a glance

  • Drugs Figitumumab (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Feb 2014 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 29 Aug 2012 New source identified and integrated (DRKS00004070: German Clinical Trials Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top